Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-center, Open-label, Controlled, Superiority, Randomized, Controlled Registration Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）

NCT06925971 is registered in ClinicalTrials.gov with MicroPort NeuroTech Co., Ltd. as lead sponsor.

NCT NCT06925971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06925971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-center, Open-label, Controlled, Superiority, Randomized, Controlled Registration Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）
Lead sponsor
MicroPort NeuroTech Co., Ltd.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
April 15, 2025
Completion date
October 1, 2027
Enrollment
279 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intracranial arteriosclerosis